David Avigan, MD
Enriched profileChief of Clinical and Scientific Integration and Vice Chair of Medical Oncology, Dana-Farber Cancer Institute; Cancer Center Director and Chief of Hematologic Malignancies, Beth Israel Deaconess Medical Center · Dana-Farber Cancer Institute
David Avigan is Chief of Clinical and Scientific Integration and Vice Chair of Medical Oncology, Dana-Farber Cancer Institute; Cancer Center Director and Chief of Hematologic Malignancies, Beth Israel Deaconess Medical Center at Dana-Farber Cancer Institute. OpenAlex indexes 563 publications with 18,699 citations (h-index 60); ClinicalTrials.gov lists 28 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
David Avigan, MD, is Chief of Clinical and Scientific Integration and Vice Chair of Medical Oncology, Dana-Farber Cancer Institute. The public record shows 563 publications with 18,699 citations (h-index 60), centered on Multiple Myeloma Research and Treatments, Immunotherapy and Immune Responses, CAR-T cell therapy research. It also documents an investigator role on 28 registered clinical trials, industry payments reported by 10 companies, 7 NIH-funded awards (1998–2026).
- Most recent indexed publication: 2026 · Blood cancer discovery
- Top research focus: Multiple Myeloma Research and Treatments
- 28 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 168.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 28 registered studies on ClinicalTrials.gov. The most recent:
- Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
Sponsor: Dana-Farber Cancer Institute
- DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Sponsor: David Avigan
Industry payments
Updated 27 Aug 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Chugai Pharmaceutical Co., Ltd.Program year20255 payments$35,315openpaymentsdata.cms.gov ↗
- Regeneron Pharmaceuticals, Inc.Program year20252 payments
- Chugai Pharmaceutical Co., Ltd.Program year20242 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Proton pump inhibitor100%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
7 NIH research awards on record, funded 1998–2026 per NIH RePORTER. The latest:
- Personalized Adoptive T-cell Therapy for AML
Beth Israel Deaconess Medical Center
FY2026$728,501R01CA262629 - Personalized Adoptive T-cell Therapy for AML
Beth Israel Deaconess Medical Center
FY2025$728,501R01CA262629 - Personalized Adoptive T-cell Therapy for AML
Beth Israel Deaconess Medical Center
FY2024$692,077R01CA262629
Congress activity
Updated 27 Aug 2026
74 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Enhancing CAR T cell responses in lymphoma through coadministration of vaccine-educated T cells
ASH Annual Meeting
ASH2025Co-author - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine
ASH Annual Meeting
ASH2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire.
Nature communications
Clinical Trial2025 - Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Science translational medicine
Article2021
Most-cited works
by citation count (OpenAlex)- 01
- 02Interleukin-2 and Regulatory T Cells in Graft-versus-Host DiseaseArticle1,121 citations2011
- 03
- 04
- 05A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenanceArticle716 citations2012
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/david-avigan-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/David-E-Avigan-2127043245
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bilh.org ↗
- Board Certified
Internal Medicine, Hematology, and Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Professor of Medicine
Theodore W. and Evelyn G. Berenson Chair of Medicine, Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Editorial & leadership roles
journal and society appointments- Editorial board member
Clinical Cancer Research (AACR)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacrjournals.org ↗
Secondary affiliations
appointments beyond the home institution- Beth Israel Deaconess Medical Center
Cancer Center Director, Senior Vice President of Cancer Services (Beth Israel Lahey Health), Chief of Hematology and Hematologic Malignancies Division
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bilh.org ↗ - Dana-Farber/Harvard Cancer Center (DF/HCC)
member of Leukemia and Lymphoma/Myeloma programs; Deputy Associate Director, Clinical Science Program; Chair, Scientific Review Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →news.harvard.edu ↗
- Featured speaker/contributor
VJHemOnc video interviews on cancer vaccines and cellular immunotherapy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗ - Interview on COVID-19 impact on cancer patient care
BIDMC Giving COVID-19 Initiatives
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →covidresponse.bidmcgiving.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute